Zobrazeno 1 - 10
of 194
pro vyhledávání: '"William J. M. Hrushesky"'
Autor:
Jamil Singletary, Patricia A. Wood, Jovelyn Du-Quiton, Song Wang, Xiaoming Yang, Shobhit Vishnoi, William J. M. Hrushesky
Publikováno v:
International Journal of Biomedical Imaging, Vol 2009 (2009)
Circadian clocks gate cellular proliferation and, thereby, therapeutically target availability within proliferative pathways. This temporal coordination occurs within both cancerous and noncancerous proliferating tissues. The timing within the circad
Externí odkaz:
https://doaj.org/article/1d5939f4432140e593c31e43bfe8fc3f
Autor:
Tim Birdsall, William J. M. Hrushesky, Dinah Faith Q. Huff, Justin Reynolds, David E. Blask, Robert D. Levin, Digant Gupta, Christopher G. Lis, James F. Grutsch, Xiaotong Shen, Patricia A. Wood, Dennis K. Pearl
Publikováno v:
Biological Rhythm Research. 53:1043-1057
Cancer patients show the signs and symptoms of a failing circadian organization. Melatonin, secreted only during nightly darkness, promotes nightly sleep and synchronizes daily molecular and physio...
Autor:
David M. Aboulafia, Bartlett J. Witherspoon, Shamia Hoque, Michael D. Wyatt, Y. Tony Yang, Paul R. Yarnold, William J. M. Hrushesky, Catherine S Hwang, Brian Chen, Paul Ray, Martin W. Schoen, Charles L. Bennett, Matthew A. Taylor, Benjamin Schooley
Publikováno v:
The Lancet Oncology. 21:e575-e588
The EU, the USA, and Japan account for the majority of biological pharmacotherapy use worldwide. Biosimilar regulatory approval pathways were authorised in the EU (2006), in Japan (2009), and in the USA (2015), to facilitate approval of biological dr
Autor:
Shamia Hoque, Michael Dickson, Paul R. Yarnold, Oliver Sartor, Bartlett J. Witherspoon, Benjamin Schooley, Chadi Nabhan, Charles L. Bennett, Brian J. Chen, William J. M. Hrushesky, Y. Tony Yang, Martin W. Schoen, Kevin B. Knopf
Publikováno v:
International Journal of Cancer. 146:2829-2835
Erythropoiesis-stimulating agents (ESAs) are available to treat chemotherapy-induced anemia (CIA). In 2007-2008, regulatory notifications advised of venous thromboembolism and mortality risks while the Center for Medicare and Medicaid Services' restr
Autor:
James O. Armitage, Shamia Hoque, Laura Rose Bobolts, LeAnn B. Norris, Sumimasa Nagai, Chadi Nabhan, Oliver Sartor, Anuhya Kommalapati, Robert C. Kane, Carlo DeAngelis, Paul R. Yarnold, Charles L. Bennett, Joshua Riente, Dennis W. Raisch, Brian Chen, Paul Ray, Ashley Caitlin Godwin, Stefano Luminari, William J. M. Hrushesky, Bryan L. Love, Bartlett J. Witherspoon, Kevin B. Knopf, Y. Tony Yang, Sri Harsha Tella
Publikováno v:
The Oncologist. 24:537-548
Biosimilar filgrastims are primarily indicated for chemotherapy-induced neutropenia prevention. They are less expensive formulations of branded filgrastim, and biosimilar filgrastim was the first biosimilar oncology drug administered in European Unio
Autor:
Andrew C Bennett, William J. M. Hrushesky, Martin W. Schoen, Mariana P. Socal, James O. Armitage, Joseph R. Berger, Chadi Nabhan, Daniele Focosi, Charles L. Bennett, Julia C Bian
Publikováno v:
The Lancet. Haematology. 8(8)
Progressive multifocal leukoencephalopathy (PML) is a serious and usually fatal CNS infection caused by the John Cunningham virus. CD4+ and CD8+ T-cell lymphopenia, resulting from HIV infection, chemotherapy, or immunosuppressive therapy, are primary
Autor:
Sumimasa Nagai, William J. M. Hrushesky, Benjamin Djulbegovic, Rebecca Tombleson, Stefano Luminari, Josh Riente, Charles L. Bennett, Laura Rose Bobolts, Andrew C Bennett, Paul R. Yarnold, Paul Ray, Kenneth R. Carson, James O. Armitage, Shamia Hoque, Chadi Nabhan, Marc L. Fishman, John Brusk, Oliver Sartor, Bart Witherspoon, Y. Tony Yang, John Restaino, Martin W. Schoen, Kevin B. Knopf
Publikováno v:
Oncologist
Biosimilars are biologic drug products that are highly similar to reference products in analytic features, pharmacokinetics and pharmacodynamics, immunogenicity, safety, and efficacy. Biosimilar epoetin received Food and Drug Administration (FDA) app
Autor:
Shamia Hoque, Kevin B. Knopf, Marc L. Fishman, Steven D. Rosen, Courtney Lubaczewski, Paul Ray, Paul R. Yarnold, Oliver Sartor, Henry C. Ausdenmoore, Matthew A. Taylor, Robert E. Marx, Benjamin Schooley, Martin W. Schoen, Y. Tony Yang, Nancy F. Olivieri, David M. Aboulafia, Jay Vemula, William J. M. Hrushesky, Juan Aldaco, Salvatore L. Ruggiero, John Restaino, Henrik S. Thomsen, Anne Ventrone, Linda Martin, June M. McKoy, William K. Smith, Georgne Herring, Ashley Caitlin Godwin, Cesar A. Migliorati, Chadi Nabhan, Charles L. Bennett, Andrew C Bennett, Bartlett J. Witherspoon, Kenneth R. Carson
Publikováno v:
EClinicalMedicine
Bennett, C L, Hoque, S, Olivieri, N, Taylor, M A, Aboulafia, D, Lubaczewski, C, Bennett, A C, Vemula, J, Schooley, B, Witherspoon, B J, Godwin, A C, Ray, P S, Yarnold, P R, Ausdenmoore, H C, Fishman, M, Herring, G, Ventrone, A, Aldaco, J, Hrushesky, W J, Restaino, J, Thomsen, H S, Marx, R, Migliorati, C, Ruggiero, S, Nabhan, C, Carson, K R, McKoy, J M, Yang, Y T, Schoen, M W, Knopf, K, Martin, L, Sartor, O, Rosen, S & Smith, W K 2021, ' Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019) : A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) ', EClinicalMedicine, vol. 31, 100693 . https://doi.org/10.1016/j.eclinm.2020.100693
EClinicalMedicine, Vol 31, Iss, Pp 100693-(2021)
Bennett, C L, Hoque, S, Olivieri, N, Taylor, M A, Aboulafia, D, Lubaczewski, C, Bennett, A C, Vemula, J, Schooley, B, Witherspoon, B J, Godwin, A C, Ray, P S, Yarnold, P R, Ausdenmoore, H C, Fishman, M, Herring, G, Ventrone, A, Aldaco, J, Hrushesky, W J, Restaino, J, Thomsen, H S, Marx, R, Migliorati, C, Ruggiero, S, Nabhan, C, Carson, K R, McKoy, J M, Yang, Y T, Schoen, M W, Knopf, K, Martin, L, Sartor, O, Rosen, S & Smith, W K 2021, ' Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019) : A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) ', EClinicalMedicine, vol. 31, 100693 . https://doi.org/10.1016/j.eclinm.2020.100693
EClinicalMedicine, Vol 31, Iss, Pp 100693-(2021)
Background: Adverse drug/device reactions (ADRs) can result in severe patient harm. We define very serious ADRs as being associated with severe toxicity, as measured on the Common Toxicity Criteria Adverse Events (CTCAE)) scale, following use of drug
Publikováno v:
Medicina
Medicina, Vol 56, Iss 468, p 468 (2020)
Medicina, Vol 56, Iss 468, p 468 (2020)
The report addresses the role of the hazard function in the analysis of disease-free survival data in breast cancer. An investigation on local recurrences after mastectomy provided evidence that uninterrupted growth is inconsistent with clinical find
Autor:
Laura Rose Bobolts, Benjamin Schooley, Bartlett J. Witherspoon, Jesse Keller, Paul R. Yarnold, Brian J. Chen, Michael Dickson, Chadi Nabhan, Kenneth R. Carson, Martin W. Schoen, Kevin B. Knopf, Shamia Hoque, Y. Tony Yang, Oliver Sartor, William J. M. Hrushesky, Paul Ray, Charles L. Bennett
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 6, p e0234541 (2020)
PLoS ONE, Vol 15, Iss 6, p e0234541 (2020)
Erythropoisis stimulating agent (ESA) use was addressed in Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) meetings between 2004 and 2008. FDA safety-focused regulatory actions occurred in 2007 and 2008. In 2007, black box